Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

FMT+ QL1706+ Bevacizumab+ Xelox als Erstlinienbehandlung für fortgeschrittene MSS-Typ-Dickdarmkrebs mit Lebermetastasierung

22. September 2026 aktualisiert von: Hua Jiang

Fäkalmikrobiota-Transplantation in Kombination mit QL1706, Bevacizumab und Xelox als Erstline

The investigators plan to initiate a prospective, multicenter, phase II study, recruiting 30 patients with advanced colorectal cancer patients with liver metastasis who have not received prior treatment. This study plans to reconstruct intestinal microecology through fecal microbiota transplantation (FMT), and combine with QL1706+Bevacizumab+XELOX to enhance the anti-tumor immune effect at the same time, thereby improving the prognosis of colorectal cancer patients with liver metastasis.

Studienübersicht

Status

Rekrutierung

Detaillierte Beschreibung

This is a prospective, single-arm, multi-center, exploratory clinical study. Patients with previously untreated, newly diagnosed advanced colorectal cancer with liver metastasis, who could be diagnosed by histological or cytological means, ECOG PS 0-1, excluded Ras, Raf wild type left colon/rectum, excluded dMMR/MSI-H. Eligible subjects who met the inclusion criteria were screened and signed informed consent.

FMT was performed 2 days after treatment with bevacizumab, and chemotherapy. QL1706, bevacizumab, and chemotherapy (XELOX) were administered every 3 weeks according to the patient's body surface area. A total of 6 cycles were performed. Subsequent maintenance therapy was at the discretion of the investigator.

RECIST v1.1 was used for tumor evaluation every 6 weeks during treatment. NCI-CTCAE 5.0 was used for safety assessment every 3 weeks. Adverse events were recorded throughout the study to 90 days after the end of treatment. Treatment continues until disease progression, subject withdraws informed consent, loss of follow-up, or death. Patients should provide 10ml whole blood samples and fecal samples at baseline, after two cycles of treatment, after four cycles of treatment, before maintenance treatment for the detection of efficacy prediction markers (each cycle is 21 days).

Studientyp

Interventionell

Einschreibung (Geschätzt)

30

Phase

  • Phase 2

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studienorte

      • Changzhou, China
        • Rekrutierung
        • The Second People's Hospital of Changzhou
        • Kontakt:
          • Hua Jiang MD
          • Telefonnummer: +86-18015852711

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre bis 75 Jahre (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  1. Histological or cytological confirmed advanced colorectal cancer with liver metastasis.
  2. Signed written informed consent.
  3. Have not received anti-tumor treatment.
  4. According to the investigators assessment, at least one measurable target lesion defined by RECIST v1.1.
  5. Patients of both sexes, aged ≥18 years and ≤75 years.
  6. ECOG PS 0-1;
  7. Expected survival time ≥ 3 months;
  8. Have adequate organ and bone marrow function, laboratory examination within 7 days prior to enrollment meets the following requirements, as follows:

1) Blood routine: ANC ≥ 1.5 × 10^9/L, Platelet count ≥ 100 × 10^9/L, HGB ≥100 g/L (no blood transfusion or erythropoietin dependence within 14 days); 2) Liver function: TBIL ≤1.5 x ULN; ALT/AST ≤ 5 x ULN; ALP ≤5×ULN; 3) Renal function: Cr ≤1.5×ULN, or creatinine clearance ≥50 mL/min: Urine routine results showed urinary protein < 2+; 4) Coagulation function: INR or PT ≤1.5 x ULN. 9.For female subjects of reproductive age, a urine or serum pregnancy test should be performed and the result is negative 3 days prior to receiving the initial study drug administration.

10. For women of childbearing potential (WOCBP): agreement to refrain from heterosexual intercourse or use contraception.

11. For men: agreement to refrain from heterosexual intercourse or use a condom, and agreement to refrain from donating sperm.

Exclusion Criteria:

  1. Suffered from other malignancies in the past 5 years, excluding cured basal cell carcinoma of the skin, cervical carcinoma in situ and papillary thyroid carcinoma.
  2. Patients requiring elective surgery during the trial.
  3. Patients who cannot take oral drugs, or have conditions that the investigator determines to significantly affect gastrointestinal absorption, such as chronic diarrhea, intestinal obstruction, etc., and are not suitable for treatment.
  4. Patients during pregnancy (positive pregnancy test) or lactation.
  5. Central nervous system metastasis or meningeal metastasis.
  6. Uncontrollable bone metastasis, or patients at risk of fracture, requiring surgery, local radiation therapy.
  7. Patients with active infection requiring systemic anti-infection treatment.
  8. Patients with a history of immunodeficiency, including those who are positive for HIV antibody tests.
  9. Patients with known, active autoimmune diseases.
  10. Patients with uncontrolled active hepatitis B, patients with hepatitis C virus infection (HCV antibody positive).
  11. A history of severe cardiovascular and cerebrovascular diseases, including but not limited to: severe arrhythmia, acute coronary syndrome within 6 months, congestive heart failure, aortic dissection, stroke, and T IA history.
  12. Severe bleeding events occur within half a year, or high bleeding risk factors such as active digestive tract ulcers and esophageal and gastric varices due to liver cirrhosis.
  13. Patients with diabetes who cannot be stably controlled by drugs (including insulin).
  14. Mental or language disorders that prevent communication with the patient;
  15. Patients participating in another clinical trial.
  16. MSI-H/ d MMR without immunotherapy; left colorectum of Ras, Raf wild-type.
  17. The investigator believes that the subject has other serious systemic diseases or other conditions that make him unsuitable for participation in this trial.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: N / A
  • Interventionsmodell: Einzelgruppenzuweisung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Fmt+ql1706+Bevacizumab+xelox

Participants will receive FMT combined with QL1706+Bevacizumab+XELOX for 6 cycles. If there is no progression of the disease after 6 cycles of the first-line treatment, then patients will enter the maintenance treatment stage. The therapy of maintenance treatment stage was at the discretion of the investigator.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Objective Response Rate (ORR)
Zeitfenster: up to 24 months

Objective response rate will be assessed by investigators.

up to 24 months

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Median Progression-Free Survival (mPFS)
Zeitfenster: up to 24 months

Observation for mPFS will be recorded until the end of follow-up after the start of 1st cycle of treatment.

up to 24 months
Median Overall Survival (mOS)
Zeitfenster: up to 24 months

The time from the first treatment to death from any cause.

up to 24 months
6-Months Progression-Free Survival Rate (6month-PFS)
Zeitfenster: up to 6 months

The proportion of patients whose disease did not progress 6 months after treatment

up to 6 months
12-Months Progression-Free Survival Rate (12month-PFS)
Zeitfenster: up to 12 months

The proportion of patients whose disease did not progress 12 months after treatment

up to 12 months
18-Months Progression-Free Survival Rate (18month-PFS)
Zeitfenster: up to 18 months

The proportion of patients whose disease did not progress 18 months after treatment

up to 18 months
6-Months overall survival rate(6-Months-OS Rate)
Zeitfenster: up to 6 months

The proportion of patients who have not died after 6-Months of treatment

up to 6 months
12-Months overall survival rate(12-Months-OS Rate)
Zeitfenster: up to 12 months

The proportion of patients whose disease did not progress 12 months after treatment

up to 12 months
18-Months overall survival rate(18-Monthsr-OS Rate)
Zeitfenster: up to 18 months

The proportion of patients who have not died after 18 months of treatment

up to 18 months
Objective Response Rate (ORR) of liver metastases
Zeitfenster: up to 24 months

Objective response rate will be assessed by investigators.

up to 24 months
Disease Control Rate (DCR)
Zeitfenster: up to 24 months

The proportion of patients whose tumors achieve a response (CR+PR) and stable disease (SD) after treatment for the minimum duration required.

up to 24 months
Surgical conversion rate
Zeitfenster: up to 24 months

Proportion of inoperable patients converted to operable.

up to 24 months
Incidence of Adverse events (AEs)
Zeitfenster: up to 24 months

Therapy-related adverse events will be recorded and assessed according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE, Version 5.0).

up to 24 months
Quality of Life (QoL)
Zeitfenster: up to 24 months

QoL(quality of life) will be evaluated by EORTC-QLQ-C30.The total score ranges from 0 to 60, with higher scores indicating better quality of life

up to 24 months
The Diversity of Fecal Microbiota
Zeitfenster: up to 24 months

This will be detected by 16s rRNA sequencing or metagenomes.

up to 24 months

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

17. April 2025

Primärer Abschluss (Geschätzt)

1. Februar 2027

Studienabschluss (Geschätzt)

1. Februar 2027

Studienanmeldedaten

Zuerst eingereicht

25. Januar 2025

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

25. Januar 2025

Zuerst gepostet (Tatsächlich)

30. Januar 2025

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

24. September 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

22. September 2026

Zuletzt verifiziert

1. September 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • [2025]YLJSA057-01

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren